Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia
- PMID: 33201424
- DOI: 10.1007/s40265-020-01433-6
Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia
Abstract
Venetoclax (Venclexta®; Venclyxto®) is a first-in-class, oral, selective inhibitor of B cell lymphoma 2 (BCL2). In several countries, including the USA and those of the EU, venetoclax is indicated in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Approval was based on the results of the phase III CLL14 trial in patients with previously untreated CLL and co-existing conditions. In this study, fixed-duration (12 months) targeted treatment with venetoclax + obinutuzumab resulted in significantly longer progression-free survival (PFS; primary endpoint) relative to fixed-duration chemoimmunotherapy with chlorambucil + obinutuzumab. Venetoclax + obinutuzumab was also associated with significantly higher rates of undetectable minimal residual disease (MRD), complete response and overall response than chlorambucil + obinutuzumab. Improvements in clinical outcomes with venetoclax + obinutuzumab were maintained during long-term follow-up, when all patients had been off treatment for ≥ 2 years. No significant between-group difference was observed in overall survival (OS). Venetoclax had an acceptable tolerability profile. Notable adverse events such as grade 3 or 4 neutropenia can be managed with supportive therapy and venetoclax dose modifications. In conclusion, fixed-duration venetoclax + obinutuzumab represents an important chemotherapy-free first-line treatment option for patients with CLL, particularly those who are not fit enough to receive intensive chemoimmunotherapy.
Similar articles
-
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5. Lancet Oncol. 2020. PMID: 32888452 Clinical Trial.
-
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2024 Jun;25(6):744-759. doi: 10.1016/S1470-2045(24)00196-7. Lancet Oncol. 2024. PMID: 38821083 Clinical Trial.
-
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.Lancet Oncol. 2021 Oct;22(10):1391-1402. doi: 10.1016/S1470-2045(21)00455-1. Epub 2021 Sep 14. Lancet Oncol. 2021. PMID: 34534514 Clinical Trial.
-
[Current diagnosis and treatment of chronic lymphocytic leukaemia].Dtsch Med Wochenschr. 2020 Aug;145(16):1139-1144. doi: 10.1055/a-1039-8472. Epub 2020 Aug 13. Dtsch Med Wochenschr. 2020. PMID: 32791549 Review. German.
-
An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.Future Oncol. 2021 Feb;17(4):371-387. doi: 10.2217/fon-2020-0640. Epub 2020 Oct 16. Future Oncol. 2021. PMID: 33064021 Review.
Cited by
-
Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS.Ann Hematol. 2024 Aug;103(8):3179-3191. doi: 10.1007/s00277-024-05676-1. Epub 2024 Feb 26. Ann Hematol. 2024. PMID: 38403712
-
An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities.Saudi J Biol Sci. 2024 Feb;31(2):103920. doi: 10.1016/j.sjbs.2023.103920. Epub 2023 Dec 30. Saudi J Biol Sci. 2024. PMID: 38283805 Free PMC article. Review.
-
The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells.Med Oncol. 2023 Jul 11;40(8):234. doi: 10.1007/s12032-023-02107-5. Med Oncol. 2023. PMID: 37432531
-
Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.Front Immunol. 2023 Jan 4;13:1070660. doi: 10.3389/fimmu.2022.1070660. eCollection 2022. Front Immunol. 2023. PMID: 36685572 Free PMC article.
References
-
- Sengar M, Jain H, Rajendra A, et al. Frontline therapy of chronic lymphocytic leukemia: changing treatment paradigm. Curr Hematol Malig Rep. 2020;15(3):168–76. - DOI
-
- Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2020. https://doi.org/10.1016/j.annonc.2020.09.019 . - DOI - PubMed
-
- Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266–87. - DOI
-
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): chronic lymphocytic leukaemia/small lymphocytic lymphoma. Version 1.2021. 2020. https://www.nccn.org . Accessed 19 Oct 2020.
-
- Von Tresckow J, Eichhorst B, Bahlo J, et al. The treatment of chronic lymphatic leukemia. Dtsch Arzebl Int. 2019;116(4):41–6.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources